S Kalra1, A Vitale, N R Cashman, A Genge, D L Arnold. 1. Department of Medicine, Division of Neurology, University of Alberta, Edmonton, Alberta, Canada. sanjay.kalra@ualberta.ca
Abstract
OBJECTIVE: To determine the relationship of cerebral degeneration with survival in amyotrophic lateral sclerosis (ALS). METHODS: Patients with probable or definite ALS underwent magnetic resonance spectroscopic imaging (MRSI) of the brain between July 1996 and May 2002, and were followed prospectively until March 2004. Creatine (Cr), choline (Cho) and the neuronal marker N-acetylaspartate (NAA) were quantified as ratios in the motor cortex. RESULTS: In 63 patients compared with 18 healthy people, NAA/Cho was reduced by 13% (p<0.001), NAA/Cr was reduced by 5% (p = 0.01) and Cho/Cr was increased by 8% (p = 0.01). NAA/Cho was used for survival analysis, given its larger effect size and superior test accuracy (a sensitivity of 67% and a specificity of 83%). Median survival after MRSI was 24 months. Multivariate analysis showed reduced survival for lower NAA/Cho (hazard ratio (HR) 0.24, 95% confidence interval (CI) 0.08 to 0.72, p = 0.01), older age (HR 1.03, 95% CI 1.00 to 1.06, p = 0.04) and shorter symptom duration (HR 0.96, 95% CI 0.93 to 0.99, p = 0.01). Patients with NAA/Cho <2.11 had a reduced survival of 19.4 v 31.9 months (HR 2.05, 95% CI 1.12 to 4.03, p = 0.02). CONCLUSIONS: Cerebral degeneration is predictive of reduced survival in ALS.
OBJECTIVE: To determine the relationship of cerebral degeneration with survival in amyotrophic lateral sclerosis (ALS). METHODS:Patients with probable or definite ALS underwent magnetic resonance spectroscopic imaging (MRSI) of the brain between July 1996 and May 2002, and were followed prospectively until March 2004. Creatine (Cr), choline (Cho) and the neuronal marker N-acetylaspartate (NAA) were quantified as ratios in the motor cortex. RESULTS: In 63 patients compared with 18 healthy people, NAA/Cho was reduced by 13% (p<0.001), NAA/Cr was reduced by 5% (p = 0.01) and Cho/Cr was increased by 8% (p = 0.01). NAA/Cho was used for survival analysis, given its larger effect size and superior test accuracy (a sensitivity of 67% and a specificity of 83%). Median survival after MRSI was 24 months. Multivariate analysis showed reduced survival for lower NAA/Cho (hazard ratio (HR) 0.24, 95% confidence interval (CI) 0.08 to 0.72, p = 0.01), older age (HR 1.03, 95% CI 1.00 to 1.06, p = 0.04) and shorter symptom duration (HR 0.96, 95% CI 0.93 to 0.99, p = 0.01). Patients with NAA/Cho <2.11 had a reduced survival of 19.4 v 31.9 months (HR 2.05, 95% CI 1.12 to 4.03, p = 0.02). CONCLUSIONS:Cerebral degeneration is predictive of reduced survival in ALS.
Authors: Stefan Sivák; Michal Bittšanský; Egon Kurča; Monika Turčanová-Koprušáková; Milan Grofik; Vladimír Nosál'; Hubert Poláček; Dušan Dobrota Journal: Neuroradiology Date: 2010-04-06 Impact factor: 2.804
Authors: M Filippi; F Agosta; S Abrahams; F Fazekas; J Grosskreutz; S Kalra; J Kassubek; V Silani; M R Turner; J C Masdeu Journal: Eur J Neurol Date: 2010-02-02 Impact factor: 6.089
Authors: Daniel Ta; Abdullah Ishaque; Ojas Srivastava; Chris Hanstock; Peter Seres; Dean T Eurich; Collin Luk; Hannah Briemberg; Richard Frayne; Angela L Genge; Simon J Graham; Lawrence Korngut; Lorne Zinman; Sanjay Kalra Journal: Neurology Date: 2021-06-14 Impact factor: 11.800
Authors: Nazem Atassi; Maosheng Xu; Christina Triantafyllou; Boris Keil; Robert Lawson; Paul Cernasov; Elena Ratti; Christopher J Long; Sabrina Paganoni; Alyssa Murphy; Nouha Salibi; Ravi Seethamraju; Bruce Rosen; Eva-Maria Ratai Journal: PLoS One Date: 2017-05-12 Impact factor: 3.240
Authors: G Grolez; C Moreau; V Danel-Brunaud; C Delmaire; R Lopes; P F Pradat; M M El Mendili; L Defebvre; D Devos Journal: BMC Neurol Date: 2016-08-27 Impact factor: 2.474